{"title":"The effect of nonsteroidal and steroid anti-inflammatory drugs on platelet activation IN VITRO","authors":"A. Bokarev, A. O. Minina, V. E. Gorokhov","doi":"10.52419/issn2072-2419.2023.4.463","DOIUrl":null,"url":null,"abstract":"The article presents the results of a study on the effect of steroid and nonsteroidal anti-inflammatory drugs on platelets.The object of the study was plasma obtained from rat blood (n=10). Blood sampling (2.0 ml from each animal) was carried out from the tail vein into test tubes with sodium citrate. Cell elements were counted directly in blood and in platelet plasma using a MEK-6550 hematological analyzer.The ability to influence platelet activation was determined in drugs such as dexamethasone, ketarol and miloxicam, which were injected into test tubes before plasma reactivation. It was found that the drugs of these groups affect the metabolism of these cells and inhibit their ability to cause clot contraction. It was found that the strength of the negative effect on clot contraction in the steroid drug dexamethasone, which through intermediaries suppresses the activity of phospholipase-A2 and the nonsteroidal drug ketarol, which is the predominant inhibitor of cyclooxygenase of the first type, are similar. It was also found out that the drug meloxicam, which is a predominant inhibitor of cyclooxygenase of the second type, causes only a slight decrease in platelet clot contraction. The results obtained in the experiment indicate a direct positive relationship between the degree of clot contraction and the amount of thromboxane-A2, which is synthesized and released by activated platelets. It is known that the ability of platelets to accelerate and enhance regenerative processes is also directly related to their activation. Based on this, it is suggested that patients who have been prescribed plateletenriched plasma therapy should not use glucocorticoids and preparations with a high degree of selectivity to cyclooxygenase of the first type as anti-inflammatory drugs.","PeriodicalId":14419,"journal":{"name":"International Journal of Veterinary Medicine","volume":" 27","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Veterinary Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52419/issn2072-2419.2023.4.463","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The article presents the results of a study on the effect of steroid and nonsteroidal anti-inflammatory drugs on platelets.The object of the study was plasma obtained from rat blood (n=10). Blood sampling (2.0 ml from each animal) was carried out from the tail vein into test tubes with sodium citrate. Cell elements were counted directly in blood and in platelet plasma using a MEK-6550 hematological analyzer.The ability to influence platelet activation was determined in drugs such as dexamethasone, ketarol and miloxicam, which were injected into test tubes before plasma reactivation. It was found that the drugs of these groups affect the metabolism of these cells and inhibit their ability to cause clot contraction. It was found that the strength of the negative effect on clot contraction in the steroid drug dexamethasone, which through intermediaries suppresses the activity of phospholipase-A2 and the nonsteroidal drug ketarol, which is the predominant inhibitor of cyclooxygenase of the first type, are similar. It was also found out that the drug meloxicam, which is a predominant inhibitor of cyclooxygenase of the second type, causes only a slight decrease in platelet clot contraction. The results obtained in the experiment indicate a direct positive relationship between the degree of clot contraction and the amount of thromboxane-A2, which is synthesized and released by activated platelets. It is known that the ability of platelets to accelerate and enhance regenerative processes is also directly related to their activation. Based on this, it is suggested that patients who have been prescribed plateletenriched plasma therapy should not use glucocorticoids and preparations with a high degree of selectivity to cyclooxygenase of the first type as anti-inflammatory drugs.